558442-97-0

Usage

Uses

Used in Pharmaceutical Synthesis:
Cyclohexanamine, 4-(4-morpholinyl)-, transis used as a key intermediate in the synthesis of various pharmaceuticals due to its ability to form essential molecular structures that contribute to the therapeutic effects of these medications.
Used in Agrochemical Production:
In the agrochemical industry, Cyclohexanamine, 4-(4-morpholinyl)-, transis utilized as a building block for the development of compounds that aid in crop protection and enhancement of agricultural yields.
Used in Rubber Chemicals:
Cyclohexanamine, 4-(4-morpholinyl)-, transis used as an intermediate in the production of rubber chemicals, which are essential for improving the properties and performance of rubber-based products.
Used in Textile Chemicals:
Cyclohexanamine, 4-(4-morpholinyl)-, transis also employed in the textile industry as an intermediate for the creation of textile chemicals that enhance the quality, durability, and appearance of textiles.
Used in Surfactant Production:
Cyclohexanamine, 4-(4-morpholinyl)-, transis used in the synthesis of surfactants, which are vital for their emulsifying, wetting, and cleaning properties in various consumer and industrial products.
Used in Neurological and Psychiatric Treatment:
Due to its potential to modulate neurotransmitter functions in the brain, Cyclohexanamine, 4-(4-morpholinyl)-, transhas applications in the treatment of neurological and psychiatric disorders, although further research and development are necessary to ensure its safety and efficacy in such applications.

InChI:InChI=1/C10H20N2O/c11-9-1-3-10(4-2-9)12-5-7-13-8-6-12/h9-10H,1-8,11H2/t9-,10-

Upstream product

• 755039-80-6 trans-dibenzyl-(4-morpholin-4-yl-cyclohexyl)-amine 
• 110-91-8 morpholine 
• 149506-79-6 4-(dibenzylamino)cyclohexanone 
• 2615-25-0 trans-1,4-cyclohexyldiamine 
• 558442-96-9 tert-butyl N-[4-(morpholin-4-yl)cyclohexyl]carbamate 
• 177906-48-8 trans-N-Boc-1,4-cyclohexanediamine 

Relevant academic research and scientific papers

TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS

This invention is to methods for treating disorders involving abnormal cellular proliferation that have developed resistance to a selective CDK4/6 inhibitor.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

New pteridinones as PLK inhibitors

Disclosed compounds of general formula (1) wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3 and R4 are defined as in claim 1, which are suitable for the trea

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

PTERIDINONES USED AS PLK (POLO LIKE KINASE) INHIBITORS

The invention relates to compounds of general formula (1), wherein L, Q1, Q2, X, Y, Ra, Rb, Rc, R1, R2, R3, and R4 are defined as indicated in claim 1. Said